Day One Biopharmaceuticals, Inc. (DAWN) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-04-27

Day One Biopharmaceuticals, Inc. (DAWN) has filed 13 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-04-27. 1 Form 8-K material event filings were reported by DAWN in the last 90 days. InsiderAlpha tracks every DAWN SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Day One Biopharmaceuticals, Inc. (DAWN)

SEC CIK	0001845337

90-Day SEC Filing Activity

Form 4 filings (90d)	13
Form 8-K filings (90d)	1
Latest Form 4 filing	2026-04-27

Recent DAWN Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-04-23	Josey John A.	Insider	D — Derivative transaction	72.3K	—	—	SEC
2026-04-23	Merendino Lauren	Chief Commercial Officer	D — Derivative transaction	60.2K	—	—	SEC
2026-04-23	Holles Natalie C.	Insider	D — Derivative transaction	57.3K	—	—	SEC
2026-04-23	Ramasastry Saira	Insider	D — Derivative transaction	40.5K	—	—	SEC
2026-04-23	York Charles N II	COO and CFO	D — Derivative transaction	312.0K	—	—	SEC
2026-04-23	VASCONCELLES MICHAEL	Head of Research and Dev.	D — Derivative transaction	4.4K	—	—	SEC
2026-04-23	Bender Jeremy	CHIEF EXECUTIVE OFFICER	D — Derivative transaction	300.0K	—	—	SEC
2026-04-23	Dubow Adam	Gen Counsel & Secretary	D — Derivative transaction	72.7K	—	—	SEC
2026-04-23	Bender Jeremy	CHIEF EXECUTIVE OFFICER	D — Derivative transaction	204.6K	—	—	SEC
2026-04-23	Bender Jeremy	CHIEF EXECUTIVE OFFICER	D — Derivative transaction	20.2K	—	—	SEC
2026-04-23	Bender Jeremy	CHIEF EXECUTIVE OFFICER	D — Derivative transaction	147.7K	—	—	SEC
2026-04-23	Bender Jeremy	CHIEF EXECUTIVE OFFICER	D — Derivative transaction	18.2K	—	—	SEC
2026-04-23	Bender Jeremy	CHIEF EXECUTIVE OFFICER	D — Derivative transaction	300.0K	—	—	SEC
2026-04-23	Bender Jeremy	CHIEF EXECUTIVE OFFICER	D — Derivative transaction	808.3K	—	—	SEC
2026-04-23	AI Day1 LLC	Insider	J — Other acquisition / disposition	12.93M	$21.50	$277.98M	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Day One Biopharmaceuticals, Inc. (DAWN). Updated in real time as new filings are submitted to the SEC.

Most-Active DAWN Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Bender Jeremy	17	—
York Charles N II	11	—
Dubow Adam	11	—
Merendino Lauren	9	—
Holles Natalie C.	8	—

Recent DAWN Form 8-K Material Events

2026-04-23 — Item 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01 · Acquisition · neutral [SEC]
Day One Biopharmaceuticals' tender offer by Servier Pharmaceuticals expired on April 22, 2026, with 88.18 million shares (85.34% of outstanding shares) validly tendered at $21.50 per share. The merger agreement was originally announced on March 6, 2026, and the tender offer comme
2026-03-09 — Item 9.01 · Acquisition · neutral [SEC]
Day One Biopharmaceuticals filed an amended 8-K/A to supplement financial disclosures related to a previously completed merger. The amendment adds audited and unaudited financial statements of the acquired target company and pro forma combined financial information, but does not
2026-03-06 — Item 1.01, 8.01, 9.01 · Acquisition · positive [SEC]
Day One Biopharmaceuticals entered into a definitive merger agreement with Servier Pharmaceuticals LLC, whereby Servier will acquire all outstanding shares of Day One at $21.50 per share in an all-cash tender offer. The transaction is subject to customary closing conditions inclu
2026-03-06 — Other · neutral [SEC]
Trading halt (T1) for DAWN. DAWN
2026-03-02 — Item 7.01, 9.01 · Clinical · positive [SEC]
Day One Biopharmaceuticals announced that its partner Ipsen Pharma received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending conditional marketing authorization of OJEMDA (tovorafenib) for treating children with r

Recent Insider Filings

2026-04-27 — AI Day1 LLC (Insider)
2026-04-23 — Bender Jeremy (CHIEF EXECUTIVE OFFICER)
2026-04-23 — VASCONCELLES MICHAEL (Head of Research and Dev.)
2026-04-23 — York Charles N II (COO and CFO)
2026-04-23 — Dubow Adam (Gen Counsel & Secretary)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in DAWN insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

DAWN Insider Trading — FAQ

What is the latest insider trade for DAWN?: Day One Biopharmaceuticals, Inc. (DAWN) had 13 insider filings in the last 90 days, with the most recent on 2026-04-27. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying DAWN stock?: 0 insider purchases of DAWN were filed in the last 90 days.
How many insiders are selling DAWN stock?: 0 insider sales of DAWN were filed in the last 90 days.
Where can I see DAWN SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every DAWN SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live DAWN dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.